ISRCTN66632312CompletedNot Applicable
A comparison of nebulized 3% hypertonic saline and epinephrine versus nebulized normal saline and epinephrine in the treatment of acute bronchiolitis
niversity of Alberta, Department of Pediatrics (Canada)0 sites46 target enrollmentStarted: September 13, 2005Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 46
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •Infants 6 weeks to 12 months of age with clinical symptoms of a viral respiratory infection (coryza or temperature = 38.0°C), first episode of wheezing, oxygen saturation = 85% but = 96%, and initial Respiratory Distress Assessment Instrument (RDAI) score = 4.
Exclusion Criteria
- •Pre-existing cardiac or pulmonary disease, previous diagnosis of asthma by a physician, any previous use of bronchodilators, severe disease requiring resuscitation room care, inability to administer medication by nebulizer, inability to obtain informed consent secondary to a language barrier, or no phone access for follow-up.
Investigators
Similar Trials
Recruiting
Phase 3
Advantages of using 5% hypertonic saline nebulization over 3% saline nebulization in children with Acute BronchiolitisCTRI/2017/08/009351Dean Research JIPMER
Completed
Phase 3
Does Nebulized 3% Hypertonic Saline Shorten the Duration of Hospitalization in Preschool Children with Acute Wheezing?preschool wheezinghypertonic salinelength of stayrandomized controlled trialTCTR20170327001none50
Completed
Phase 2
the effect of Nebulized Hypertonic3% Saline in the Treatment of Acute bronchiolitis in pediatric wardbrochiolitis.Acute bronchiolitis due to respiratory syncytial virusIRCT2012110510222N2Vice Chancellor for Research, Shahrekord Univrsity of Medical Sciences70
Completed
Phase 4
comparison of 2 drugs to manage brain swelling in patients with head injuryCTRI/2016/04/006829IMHANS38
Unknown
Phase 1
Hypertonic Saline 3% Nebulizer versus intravenous hypertonic saline 3% in ARDSPACTR201909691980023amr sobhy abdelkway104